Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Santaris, Nitto Denko, BASF, and More

Premium

Title: Modified Dicer Polypeptide and Methods of Use Thereof

Patent Number: 8,440,430

Filed: March 18, 2009

Lead Inventor: Jennifer Doudna, University of California, Oakland

The patent, its abstract states, relates to a “modified Dicer polypeptide … [that] exhibits enhanced catalytic activity. Also provided is a method for producing small regulatory RNAs from a dsRNA [by] contacting a dsRNA with a … modified Dicer. Small regulatory RNAs produced by a subject method find use in a variety of applications, including research and therapeutic applications.”


Title: Combination Treatment for the Treatment of Hepatitis C Virus Infection

Patent Number: 8,440,637

Filed: July 26, 2010

Inventor: Joacim Elmen, Santaris Pharma

The invention, the patent’s abstract states, relates to the “use of a combination of an inhibitor of miR-122 and an inhibitor of [very low-density lipoprotein] assembly for the treatment of HCV, hyperlipidemia, and hypercholesterolemia.”


Title: Method of Producing Lipid Nanoparticles for Drug Delivery

Application Number: 20130115274

Filed: Nov. 5, 2012

Lead Inventor: Victor Knopov, Nitto Denko

The patent application, its abstract states, claims “a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer [such as an] siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water-miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35 percent ethanol in water. The final charge ratio of drug/lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm.”


Title: siRNA that Inhibits WT1 Gene Expression and Uses Thereof

Application Number: 20130115696

Filed: Oct. 24, 2012

Lead Inventor: Haruo Sugiyama, Osaka University

The invention is based on the discovery that “siRNAs targeting the 17AA site of the WT1 gene not only suppress the expression of the WT1 gene, but also demonstrate remarkable cell growth-suppressing effects and cell death-inducing effects in cancer cell lines,” the patent application’s abstract states.


Title: Method for Transfecting Nucleic Acid to Cell and Nucleic Acid Complex

Application Number: 20130115700

Filed: July 7, 2011

Inventor: Masayuki Fujii, Kitakyushu Foundation for the Advancement of Industry, Science, and Technology

The invention, the patent application’s abstract states, relates to a method for transacting nucleic acids to cells using a nucleic acid complex created by bringing a “double-stranded nucleic acid molecule into contact with a nucleic acid carrier.”


Title: Method and Substances for Isolation and Detection of Small Polynucleotides

Application Number: 20130116154

Filed: Nov. 15, 2012

Lead Inventor: Elliott Dawson, Bioventures

The invention comprises a “capture probe suitable for use with methods for isolating, labeling, or detecting small polynucleotides,” according to the patent application’s abstract. The invention also features “a method for isolating a small polynucleotide of interest from a sample [by] hybridizing the small polynucleotide to the capture probe and lengthening the small polynucleotide by primer extension or ligation … [as well as] a method for detecting a small polynucleotide of interest following isolation by amplification of the primer extension products and/or hybridization and subsequent cleavage of dual-labeled detector probes.”


Title: Method and Compositions for the Inhibition of HIV-1 Replication

Application Number: 20130116305

Filed: Oct. 12, 2012

Lead Inventor: Sharon Wahl, US Department of Health and Human Services

The invention, the patent application’s abstract states, “relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 expression to attenuate such replication … [and] the use of antisense P21 oligonucleotides [or] siRNA[s] … to attenuate such replication.”


Title: Novel microRNA Precursor and Methods of Use for Regulation of Target Gene Expression

Application Number: 20130117885

Filed: June 28, 2011

Lead Inventor: Yuwen Wang, BASF Plant Science

The patent application, according to its abstract, claims “methods for modulating target gene expression in plants by expression of recombinant microRNA precursors. … Uses of the said recombinant microRNA precursors for the control of nematodes, in particular the control of soybean cyst nematodes, are also provided. Methods for introduction of genetic material into plants that are susceptible to nematodes in order to increase resistance to nematodes are further provided.”

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.